Less than a year after infant KJ Muldoon became the first person to receive a bespoke CRISPR gene-editing treatment, the scientists, clinicians, and technology innovators who made his therapy possible are rapidly moving to turn this success into a repeatable platform. This blueprint could slash the time and cost needed to create personalized gene-editing medicines for many more patients. It won’t be easy, but if this effort succeeds, the breakthrough that saved a single child could open the door to tailored therapies for many of the 400 million people living with rare genetic diseases worldwide.
The race to save KJ began as a rapid-response collaboration between Children’s Hospital of Philadelphia (CHOP), the University of Pennsylvania, and several industry partners. Together, they built a CRISPR therapy specifically for his rare mutation, which causes CPS1 (carbamoyl phosphate synthetase 1) deficiency. This life-threatening disorder prevents the body from removing ammonia from the bloodstream and has an estimated mortality of 50 percent in early infancy. A process that would ordinarily take 18 to 24 months was accomplished in just six, thanks to unprecedented coordination across scientific, manufacturing, and regulatory domains.
This achievement provides a replicable framework for accelerating complex, customized CRISPR therapies to patients. Academic and industry experts are working together to drive critical advances in gene editing that, with continued collaboration, will improve efforts to move gene editing from concept to clinic at record speed.
These efforts were reinforced in November, when the FDA announced the launch of a new “plausible mechanism pathway” to accelerate the approval process for bespoke, personalized therapies. The pathway is modeled on the process that led to KJ’s successful therapy, FDA officials explained in a New England Journal of Medicine editorial.
Improving off-target nomination and confirmation
Creating KJ’s therapy required a trio of innovations: a novel guide RNA (gRNA) sequence to target his unique mutation, an mRNA-encoded base editor, and a lipid nanoparticle (LNP) to deliver the editing machinery directly into his liver cells. Researchers also built patient-specific preclinical models, using them for toxicology testing and to ensure the CRISPR process would not result in off-target gene editing.
Emerging technologies are making it faster and easier to spot off-target effects in gene-editing therapies. Researchers now combine computer-based predictions with lab experiments to map potential off-target sites, generating critical insights that guide the selection of the most precise RNA guides.
At the same time, confirmation tools are becoming more sensitive and sophisticated. Technologies like high-throughput amplicon sequencing are making it possible to identify even tiny genetic changes, including small indels, base edits, and chromosomal aberrations. This level of sensitivity meets the growing expectations of the FDA and other regulatory agencies, which increasingly require therapies to demonstrate not just effectiveness, but a detailed, high-resolution understanding of any unintended edits.
Delivery beyond the liver
Improving the delivery of CRISPR components will be essential to advancing gene editing therapies. While KJ’s treatment was delivered directly to his liver, reaching other organs and tissues with the same precision will be crucial to tackling a broader range of genetic diseases. To achieve that goal, researchers are exploring a variety of innovative delivery strategies, each aimed at safely and efficiently guiding gene-editing tools exactly where they’re needed in the body.
In addition to refining LNPs, CRISPR researchers are testing alternatives to traditional viral delivery methods like adeno-associated viruses (AAVs). Promising options include extracellular vesicles and virus-like particles, both of which are capable of transporting large CRISPR cargos into a variety of target cells.
Other teams are optimizing the CRISPR enzymes delivered as mRNA — the same approach used for KJ’s treatment. In his case, the custom mRNA was designed to express a Cas9 variant fused to a base editor. Today, there are new, smaller Cas variants under development, as well as other advances that could further improve the efficiency of CRISPR delivery and help lower the risk of off-target editing.
Platforms over products
For biotech companies aiming to build CRISPR platforms, the path forward starts with building modular components that can be reused across multiple therapies. By reusing core components, such as the base editor and LNP, and swapping in disease-specific guide RNAs, developers can target a wide range of genetic mutations more efficiently.
The FDA’s Platform Technology Designation Program, launched in 2024, supports this vision by allowing developers to reuse previously approved CRISPR components to create new gene-editing therapies — without having to perform additional safety testing. The newly introduced plausible mechanism pathway takes this further, allowing companies to test safety and efficacy in very small patient groups rather than large, randomized clinical trials. Developers are still expected to gather real-world evidence to confirm long-term effectiveness and ensure that off-target effects are minimized, providing a careful balance between speed and safety.
The platform approach is now moving from concept to reality. In October, two of the clinicians who helped develop KJ’s therapy announced plans to seek FDA clearance for a new clinical trial. This trial will be open to patients with seven different urea cycle disorders, each caused by a single-gene mutation that, like KJ’s condition, could potentially be corrected with CRISPR.
Collaboration, not just science
All of this represents a major leap forward for patients with rare and life-threatening diseases. However, meaningful progress in platform-based development will depend on active industry engagement and a regulatory framework that addresses not just clinical safety, but the complex realities of manufacturing and quality assurance.
Sustainable access to personalized genetic medicines requires more than breakthroughs at the bench. It calls for rapid, cross-functional collaboration to accelerate development timelines, standardized preclinical validation to ensure safety and efficacy, and continuous dialogue with regulators to build trust, maintain quality, and minimize delays.
Early and ongoing engagement with regulatory agencies will be critical to advancing CRISPR cures, not just to navigate approvals, but to help shape the rules themselves. By standardizing documentation and manufacturing processes from the start, developers can create therapies that are both scalable and adaptable, laying the groundwork for broader, more equitable access to life-saving gene-editing treatments.
The economic case for a platform approach to CRISPR therapies is hard to ignore. Rare diseases cost the US economy almost $1 trillion per year, including $449 billion in direct medical costs and $437 billion in indirect costs from productivity losses such as absenteeism and forced retirement. Early intervention with gene editing could dramatically reduce these costs while transforming the lives of millions of patients and their families.
KJ’s case offers a roadmap for future CRISPR cures. Rapid, cross-functional collaboration can compress timelines. Standardized preclinical validation ensures therapies are both safe and effective. Frequent, proactive communication with regulators helps prevent delays and builds trust. With continued technological innovation, the industry can refine these practices, streamline CRISPR workflows, and ultimately bring personalized gene-editing therapies to a broader population of patients faster than ever before.
